Litcius/Paper detail

Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer

Yuki Sato, Hiromitsu Sumikawa, Ryota Shibaki, Takeshi Morimoto, Yoshihiko Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Hirotaka Matsumoto, Takashi Yokoi, Kazuki Hashimoto, Hiroshi Kobe, Aoi Hino, Megumi Inaba, Yoko Tsukita, Hideki Ikeda, Daisuke Arai, Hirotaka Maruyama, Satoshi Hara, Shinsuke Tsumura, Shinya Sakata, Daichi Fujimoto

2022CHEST Journal40 citationsDOI

Topics & Concepts

MedicineOsimertinibLung cancerCommon Terminology Criteria for Adverse EventsInternal medicineEpidermal growth factor receptorPneumonitisHazard ratioHypersensitivity pneumonitisInterstitial lung diseaseOncologyBronchoalveolar lavageGastroenterologyPneumoniaPathologyLungCancerErlotinibConfidence intervalLung Cancer Treatments and MutationsInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Myeloid Leukemia Treatments
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer | Litcius